781 related articles for article (PubMed ID: 17178259)
1. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance.
Neuvonen PJ; Niemi M; Backman JT
Clin Pharmacol Ther; 2006 Dec; 80(6):565-81. PubMed ID: 17178259
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Neuvonen PJ; Backman JT; Niemi M
Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors.
Williams D; Feely J
Clin Pharmacokinet; 2002; 41(5):343-70. PubMed ID: 12036392
[TBL] [Abstract][Full Text] [Related]
4. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
Neuvonen PJ
Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions.
Shitara Y; Sugiyama Y
Pharmacol Ther; 2006 Oct; 112(1):71-105. PubMed ID: 16714062
[TBL] [Abstract][Full Text] [Related]
6. Drug-drug interactions that interfere with statin metabolism.
Hirota T; Ieiri I
Expert Opin Drug Metab Toxicol; 2015; 11(9):1435-47. PubMed ID: 26058399
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes.
Kudo T; Hisaka A; Sugiyama Y; Ito K
Drug Metab Dispos; 2013 Feb; 41(2):362-71. PubMed ID: 23139378
[TBL] [Abstract][Full Text] [Related]
8. Equally potent inhibitors of cholesterol synthesis in human hepatocytes have distinguishable effects on different cytochrome P450 enzymes.
Cohen LH; van Leeuwen RE; van Thiel GC; van Pelt JF; Yap SH
Biopharm Drug Dispos; 2000 Dec; 21(9):353-64. PubMed ID: 11523064
[TBL] [Abstract][Full Text] [Related]
9. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6)-mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug-drug interaction between cerivastatin and gemfibrozil.
Shitara Y; Hirano M; Sato H; Sugiyama Y
J Pharmacol Exp Ther; 2004 Oct; 311(1):228-36. PubMed ID: 15194707
[TBL] [Abstract][Full Text] [Related]
10. HMG-CoA Reductase Inhibitors (Statins) and their Drug Interactions Involving CYP Enzymes, P-glycoprotein and OATP Transporters-An Overview.
Balasubramanian R; Maideen NMP
Curr Drug Metab; 2021; 22(5):328-341. PubMed ID: 33459228
[TBL] [Abstract][Full Text] [Related]
11. Drug-drug interactions between HMG-CoA reductase inhibitors (statins) and antiviral protease inhibitors.
Chauvin B; Drouot S; Barrail-Tran A; Taburet AM
Clin Pharmacokinet; 2013 Oct; 52(10):815-31. PubMed ID: 23703578
[TBL] [Abstract][Full Text] [Related]
12. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4.
Li DQ; Kim R; McArthur E; Fleet JL; Bailey DG; Juurlink D; Shariff SZ; Gomes T; Mamdani M; Gandhi S; Dixon S; Garg AX
CMAJ; 2015 Feb; 187(3):174-180. PubMed ID: 25534598
[TBL] [Abstract][Full Text] [Related]
13. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport.
Sakaeda T; Fujino H; Komoto C; Kakumoto M; Jin JS; Iwaki K; Nishiguchi K; Nakamura T; Okamura N; Okumura K
Pharm Res; 2006 Mar; 23(3):506-12. PubMed ID: 16388406
[TBL] [Abstract][Full Text] [Related]
14. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations.
Prueksaritanont T; Ma B; Tang C; Meng Y; Assang C; Lu P; Reider PJ; Lin JH; Baillie TA
Br J Clin Pharmacol; 1999 Mar; 47(3):291-8. PubMed ID: 10215754
[TBL] [Abstract][Full Text] [Related]
15. Cyclosporine markedly raises the plasma concentrations of repaglinide.
Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
[TBL] [Abstract][Full Text] [Related]
16. [Incremental effect and mechanism of cyclosporine on blood concentration of statins and statin package insert information in Japan].
Hirata-Koizumi M; Saito M; Miyake S; Hasegawa R
Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku; 2005; (123):37-40. PubMed ID: 16541750
[TBL] [Abstract][Full Text] [Related]
17. New insights into the pharmacodynamic and pharmacokinetic properties of statins.
Corsini A; Bellosta S; Baetta R; Fumagalli R; Paoletti R; Bernini F
Pharmacol Ther; 1999 Dec; 84(3):413-28. PubMed ID: 10665838
[TBL] [Abstract][Full Text] [Related]
18. Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus.
Lemahieu WP; Hermann M; Asberg A; Verbeke K; Holdaas H; Vanrenterghem Y; Maes BD
Am J Transplant; 2005 Sep; 5(9):2236-43. PubMed ID: 16095503
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of Organic Anion Transporting Polypeptide (OATP) 1B1 Transport Function by Lysosomotropic Drug Chloroquine: Implication in OATP-Mediated Drug-Drug Interactions.
Alam K; Pahwa S; Wang X; Zhang P; Ding K; Abuznait AH; Li L; Yue W
Mol Pharm; 2016 Mar; 13(3):839-51. PubMed ID: 26750564
[TBL] [Abstract][Full Text] [Related]
20. Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitors.
Jacobson TA
Am J Cardiol; 2004 Nov; 94(9):1140-6. PubMed ID: 15518608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
